Every round on record, with the sources behind each and the investors on them.
A biotechnology company developing placenta-targeted mRNA medicines for serious maternal and fetal disorders
emvenatx.comLinkedInPhiladelphiaBiotechFounded 2026
4 sources
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The amount was not disclosed; the $50 million figure is the fund's size, not this financing.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Seed | n/a | 2026-11-04 | not stated | 4 outlets. #52 in Trending |
4 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 4 sources The amount was not disclosed; the $50 million figure is the fund's size, not this financing. | ||||
Emvena Therapeutics is developing medicines designed to be delivered directly to the placenta to address serious maternal and fetal conditions.
Preeclampsia affects an estimated 2%–8% of pregnancies worldwide and has no approved therapy that addresses the underlying disease, leaving clinicians limited to symptom management and, in severe cases, premature delivery. Emvena is betting that its placenta-targeted lipid nanoparticles can turn preclinical mouse results—reduced hypertension and improved placental and fetal health—into an IND-enabling therapeutic platform for preeclampsia and other underserved maternal and fetal conditions.
Checked against 10 sources today